David Boyer, MD

APL-2 slows growth of GA in phase II safety and efficacy trialTwelve-month results of the FILLY trial show that in patients with geographic atrophy, the administration of complement C3 inhibitor APL-2 slowed the growth rate of the disease. It also appeared to increase the risk of new onset AMD, although this did not have an adverse effect on visual outcomes.
ALG-1001: Turning off the machinery of angiogenesisALG-1001 (Luminate, Allegro Ophthalmics) has a number of different mechanisms of action that benefit patients chronically treated with anti-vascular endothelial growth factor drugs and those who are treatment naïve.
Promising results with implantable mini telescope for end-stage AMDA 5-year study of the implantable miniature telescope for bilateral, end-stage age-related macular degeneration found positive results with a few complications.
Dexamethasone for DME delivers long-term visual benefitsA dexamethasone implant provides long-term visual improvements in patients with diabetic macular edema treated with two doses of the drug.
Long-term delivery strategies for neovascular AMDThe chronicity of neovascular age-related macular degeneration and the burden of frequent intravitreal anti-vascular endothelial growth factor injections are driving research to develop long-term delivery therapeutic strategies.